Protective CD8 T cell-mediated immunity against influenza a virus infection following influenza virus-like particle vaccination

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2486-2494

  Hemann, Emily A ^a   Kang, Sang Moo ^b   Legge, Kevin L ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS LIKE PARTICLE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS MATRIX 1 PROTEIN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DRUG RESEARCH; INFLUENZA A; INFLUENZA VACCINATION; LUNG PARENCHYMA; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL MATRIX PROTEINS;

EID: 84883409187     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300954     Document Type: Article

References (63)

1. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, C. B. Bridges, N. J. Cox, and K. Fukuda. 2004. Influenza-associated hospitalizations in the United States. JAMA 292: 1333-1340.
2. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
3. Topham, D. J., R. A. Tripp, and P. C. Doherty. 1997. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159: 5197-5200.
4. Bender, B. S., T. Croghan, L. Zhang, and P. A. Small, Jr. 1992. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 175: 1143-1145.
5. Bodewes, R., P. L. Fraaij, J. H. Kreijtz, M. M. Geelhoed-Mieras, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2012. Annual influenza vaccination affects the development of heterosubtypic immunity. Vaccine 30: 7407-7410.
6. Combadiere, B., A. Vogt, B. Mahe, D. Costagliola, S. Hadam, O. Bonduelle, W. Sterry, S. Staszewski, H. Schaefer, S. van der Werf, et al. 2010. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS ONE 5: e10818.
7. Blackburne, B. P., A. J. Hay, and R. A. Goldstein. 2008. Changing selective pressure during antigenic changes in human influenza H3. PLoS Pathog. 4: e1000058.
8. Effros, R. B., P. C. Doherty, W. Gerhard, and J. Bennink. 1977. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J. Exp. Med. 145: 557-568.
9. Yap, K. L., G. L. Ada, and I. F. McKenzie. 1978. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273: 238-239.
10. Brown, L. E., and A. Kelso. 2009. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol. Cell Biol. 87: 300-308.
11. Hillaire, M. L., A. D. Osterhaus, and G. F. Rimmelzwaan. 2011. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J. Biomed. Biotechnol. 2011: 939860.
12. Quan, F. S., C. Huang, R. W. Compans, and S. M. Kang. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81: 3514-3524.
13. Bright, R. A., D. M. Carter, S. Daniluk, F. R. Toapanta, A. Ahmad, V. Gavrilov, M. Massare, P. Pushko, N. Mytle, T. Rowe, et al. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25: 3871-3878.
14. Quan, F. S., M. C. Kim, B. J. Lee, J. M. Song, R. W. Compans, and S. M. Kang. 2012. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 430: 127-135.
15. Quan, F. S., D. Steinhauer, C. Huang, T. M. Ross, R. W. Compans, and S. M. Kang. 2008. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26: 3352-3361.
16. Quan, F. S., D. G. Yoo, J. M. Song, J. D. Clements, R. W. Compans, and S. M. Kang. 2009. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J. Virol. 83: 4489-4497.
17. Song, H., V. Wittman, A. Byers, T. Tapia, B. Zhou, W. Warren, P. Heaton, and K. Connolly. 2010. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 28: 5524-5532.
18. Legge, K. L., and T. J. Braciale. 2005. Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity 23: 649-659.
19. Legge, K. L., and T. J. Braciale. 2003. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 18: 265-277.
20. McGill, J., N. Van Rooijen, and K. L. Legge. 2008. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J. Exp. Med. 205: 1635-1646.
21. Wlodarczyk, M. F., A. R. Kraft, H. D. Chen, L. L. Kenney, and L. K. Selin. 2013. Anti-IFN-gamma and peptide-tolerization therapies inhibit acute lung injury induced by cross-reactive influenza A-specific memory T cells. J. Immunol. 190: 2736-2746.
22. Langlois, R. A., D. K. Meyerholz, R. A. Coleman, R. T. Cook, T. J. Waldschmidt, and K. L. Legge. 2010. Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming mice. Alcohol. Clin. Exp. Res. 34: 1425-1431.
23. Castilow, E. M., K. L. Legge, and S. M. Varga. 2008. Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 181: 6692-6696.
24. Stetson, D. B., M. Mohrs, V. Mallet-Designe, L. Teyton, and R. M. Locksley. 2002. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity 17: 191-200.
25. Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl, and M. K. Jenkins. 2007. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213.
26. Obar, J. J., K. M. Khanna, and L. Lefrancois. 2008. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28: 859-869.
27. Belz, G. T., C. M. Smith, L. Kleinert, P. Reading, A. Brooks, K. Shortman, F. R. Carbone, and W. R. Heath. 2004. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc. Natl. Acad. Sci. USA 101: 8670-8675.
28. GeurtsvanKessel, C. H., M. A. Willart, L. S. van Rijt, F. Muskens, M. Kool, C. Baas, K. Thielemans, C. Bennett, B. E. Clausen, H. C. Hoogsteden, et al. 2008. Clearance of influenza virus from the lung depends on migratory langerin+ CD11b- but not plasmacytoid dendritic cells. J. Exp. Med. 205: 1621-1634.
29. Kim, T. S., and T. J. Braciale. 2009. Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS ONE 4: e4204.
30. Brincks, E. L., A. Katewa, T. A. Kucaba, T. S. Griffith, and K. L. Legge. 2008. CD8 T cells utilize TRAIL to control influenza virus infection. J. Immunol. 181: 4918-4925.
31. McGill, J., and K. L. Legge. 2009. Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J. Immunol. 183: 4177-4181.
32. Moyron-Quiroz, J. E., J. Rangel-Moreno, K. Kusser, L. Hartson, F. Sprague, S. Goodrich, D. L. Woodland, F. E. Lund, and T. D. Randall. 2004. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10: 927-934.
33. Marshall, D. R., S. J. Turner, G. T. Belz, S. Wingo, S. Andreansky, M. Y. Sangster, J. M. Riberdy, T. Liu, M. Tan, and P. C. Doherty. 2001. Measuring the diaspora for virus-specific CD8+ T cells. Proc. Natl. Acad. Sci. USA 98: 6313-6318.
34. Kohlmeier, J. E., S. C. Miller, and D. L. Woodland. 2007. Cutting edge: Antigen is not required for the activation and maintenance of virus-specific memory CD8 + T cells in the lung airways. J. Immunol. 178: 4721-4725.
35. Hogan, R. J., E. J. Usherwood, W. Zhong, A. A. Roberts, R. W. Dutton, A. G. Harmsen, and D. L. Woodland. 2001. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166: 1813-1822.
36. Roberts, A. D., and D. L. Woodland. 2004. Cutting edge: effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung. J. Immunol. 172: 6533-6537.
37. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
38. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
39. Kaech, S. M., and R. Ahmed. 2001. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2: 415-422.
40. Topham, D. J., M. R. Castrucci, F. S. Wingo, G. T. Belz, and P. C. Doherty. 2001. The role of antigen in the localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia. J. Immunol. 167: 6983-6990.
41. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88.
42. Virelizier, J. L. 1975. Host defenses against influenza virus: the role of antihemagglutinin antibody. J. Immunol. 115: 434-439.
43. Krause, J. C., T. Tsibane, T. M. Tumpey, C. J. Huffman, R. Albrecht, D. L. Blum, I. Ramos, A. Fernandez-Sesma, K. M. Edwards, A. Garcia-Sastre, et al. 2012. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J. Virol. 86: 6334-6340.
44. Epstein, S. L., and G. E. Price. 2010. Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 9: 1325-1341.
45. Grebe, K. M., J. W. Yewdell, and J. R. Bennink. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10: 1024-1029.
46. Ream, R. M., J. Sun, and T. J. Braciale. 2010. Stimulation of naive CD8+ T cells by a variant viral epitope induces activation and enhanced apoptosis. J. Immunol. 184: 2401-2409.
47. Hufford, M. M., T. S. Kim, J. Sun, and T. J. Braciale. 2011. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J. Exp. Med. 208: 167-180.
48. Margine, I., L. Martinez-Gil, Y. Y. Chou, and F. Krammer. 2012. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS ONE 7: e51559.
49. Corti, D., J. Voss, S. J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S. G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
50. Ekiert, D. C., R. H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H. J. Korse, B. Brandenburg, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
51. Song, J. M., C. W. Choi, S. O. Kwon, R. W. Compans, S. M. Kang, and S. I. Kim. 2011. Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity. J. Proteome Res. 10: 3450-3459.
52. Ballesteros-Tato, A., B. Leon, F. E. Lund, and T. D. Randall. 2010. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat. Immunol. 11: 216-224.
53. Langlois, R. A., A. Varble, M. A. Chua, A. Garcia-Sastre, and B. R. Tenoever. 2012. Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses. Proc. Natl. Acad. Sci. USA 109: 12117-12122.
54. den Haan, J. M., S. M. Lehar, and M. J. Bevan. 2000. CD8(+) but not CD8(2) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192: 1685-1696.
55. Norbury, C. C., M. F. Princiotta, I. Bacik, R. R. Brutkiewicz, P. Wood, T. Elliott, J. R. Bennink, and J. W. Yewdell. 2001. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J. Immunol. 166: 4355-4362.
56. Cella, M., M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, and A. Lanzavecchia. 1999. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189: 821-829.
57. Lopez, C. B., A. Garcia-Sastre, B. R. Williams, and T. M. Moran. 2003. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J. Infect. Dis. 187: 1126-1136.
58. Moltedo, B., W. Li, J. S. Yount, and T. M. Moran. 2011. Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection. PLoS Pathog. 7: e1002345.
59. Beignon, A. S., M. Skoberne, and N. Bhardwaj. 2003. Type I interferons promote cross-priming: more functions for old cytokines. Nat. Immunol. 4: 939-941.
60. Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, et al. 2011. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208: 1989-2003.
61. Dresch, C., Y. Leverrier, J. Marvel, and K. Shortman. 2012. Development of antigen cross-presentation capacity in dendritic cells. Trends Immunol. 33: 381-388.
62. Khurana, S., J. Wu, N. Verma, S. Verma, R. Raghunandan, J. Manischewitz, L. R. King, E. Kpamegan, S. Pincus, G. Smith, et al. 2011. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J. Virol. 85: 10945-10954.
63. Lopez-Macias, C., E. Ferat-Osorio, A. Tenorio-Calvo, A. Isibasi, J. Talavera, O. Arteaga-Ruiz, L. Arriaga-Pizano, S. P. Hickman, M. Allende, K. Lenhard, et al. 2011. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29: 7826-7834.